Stock listing
gettex:IQT0 Inhibikase Therapeutics, Inc. Aktie
German listing (gettex) of Inhibikase Therapeutics, Inc. · home listing NASDAQ:IKT
Follow Inhibikase Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:IKT
$1.48 USD -0.06 (-3.9%)
Close on Nov 3, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IKT
- Day range
- $1.47 – $1.59 USDNov 3, 2026
- Volume
- 601,074 sharesNov 3, 2026
- Market cap
- $206.5M USDAt the close on Nov 3, 2026 · price × 139.5M shares outstanding
- 52-week range
- $1.39 – $2.61 USDLowest and highest trades, Nov 4, 2025 – Nov 3, 2026
- Traded on an average day
- $1.20M USDMedian day 448,216 shares · last 3 months, Aug 3, 2026 – Nov 3, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IKT · Home | $1.48 USD | -0.06 (-3.9%) | 601,074 | $1.57 | $1.59 | $1.47 | $1.54 | Close on Nov 3, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 3, 2026 · NASDAQ:IKT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.48 | -0.06 | -3.9% | $1.57 | $1.59 | $1.47 | 601,074 | |
| $1.54 | -0.01 | -0.6% | $1.56 | $1.59 | $1.47 | 449,231 | |
| $1.55 | -0.12 | -7.2% | $1.67 | $1.67 | $1.525 | 437,986 | |
| $1.67 | +0.05 | +3.1% | $1.64 | $1.695 | $1.625 | 852,337 | |
| $1.62 | +0.05 | +3.2% | $1.55 | $1.63 | $1.53 | 386,644 | |
| $1.57 | +0.05 | +3.3% | $1.55 | $1.60 | $1.495 | 1,186,220 | |
| $1.52 | -0.07 | -4.4% | $1.60 | $1.60 | $1.50 | 860,469 | |
| $1.59 | -0.04 | -2.5% | $1.60 | $1.65 | $1.541 | 408,529 | |
| $1.63 | -0.03 | -1.8% | $1.65 | $1.65 | $1.58 | 310,490 | |
| $1.66 | -0.05 | -2.9% | $1.71 | $1.76 | $1.64 | 529,005 | |
| $1.71 | +0.065 | +4.0% | $1.65 | $1.75 | $1.63 | 363,421 | |
| $1.645 | -0.005 | -0.3% | $1.67 | $1.72 | $1.57 | 1,331,840 | |
| $1.65 | -0.18 | -9.8% | $1.82 | $1.82 | $1.65 | 917,200 | |
| $1.83 | +0.03 | +1.7% | $1.80 | $1.87 | $1.795 | 400,700 | |
| $1.80 | +0.04 | +2.3% | $1.73 | $1.865 | $1.72 | 1,578,900 | |
| $1.76 | -0.085 | -4.6% | $1.85 | $1.875 | $1.73 | 1,164,500 | |
| $1.845 | -0.125 | -6.3% | $1.95 | $1.95 | $1.77 | 741,400 | |
| $1.97 | +0.06 | +3.1% | $1.90 | $1.98 | $1.87 | 435,000 | |
| $1.91 | -0.03 | -1.5% | $1.94 | $1.94 | $1.86 | 417,300 | |
| $1.94 | -0.04 | -2.0% | $1.95 | $2.00 | $1.925 | 444,000 | |
| $1.98 | -0.02 | -1.0% | $1.97 | $2.04 | $1.95 | 583,800 | |
| $2.00 | 0.00 | 0.0% | $2.00 | $2.025 | $1.955 | 407,300 | |
| $2.00 | +0.07 | +3.6% | $1.96 | $2.016 | $1.932 | 434,500 | |
| $1.93 | -0.125 | -6.1% | $2.095 | $2.095 | $1.93 | 474,700 | |
| $2.055 | +0.035 | +1.7% | $2.03 | $2.08 | $1.99 | 579,500 | |
| $2.02 | -0.03 | -1.5% | $2.03 | $2.05 | $2.005 | 400,300 | |
| $2.05 | -0.01 | -0.5% | $2.05 | $2.065 | $1.94 | 765,100 | |
| $2.06 | -0.04 | -1.9% | $2.10 | $2.15 | $2.045 | 447,200 | |
| $2.10 | -0.05 | -2.3% | $2.15 | $2.17 | $2.08 | 499,100 | |
| $2.15 | -0.16 | -6.9% | $2.30 | $2.31 | $2.14 | 412,300 | |
| $2.31 | +0.11 | +5.0% | $2.23 | $2.335 | $2.21 | 468,700 | |
| $2.20 | -0.10 | -4.3% | $2.31 | $2.32 | $2.195 | 366,000 | |
| $2.30 | 0.00 | 0.0% | $2.31 | $2.345 | $2.28 | 3,209,700 | |
| $2.30 | -0.01 | -0.4% | $2.31 | $2.365 | $2.285 | 475,500 | |
| $2.31 | 0.00 | 0.0% | $2.32 | $2.345 | $2.26 | 370,500 | |
| $2.31 | -0.08 | -3.3% | $2.40 | $2.40 | $2.253 | 480,900 | |
| $2.39 | +0.05 | +2.1% | $2.34 | $2.425 | $2.34 | 482,900 | |
| $2.34 | +0.01 | +0.4% | $2.37 | $2.39 | $2.323 | 303,200 | |
| $2.33 | -0.08 | -3.3% | $2.37 | $2.385 | $2.32 | 332,400 | |
| $2.41 | -0.02 | -0.8% | $2.43 | $2.45 | $2.38 | 323,400 | |
| $2.43 | -0.07 | -2.8% | $2.45 | $2.525 | $2.43 | 310,500 | |
| $2.50 | -0.02 | -0.8% | $2.49 | $2.55 | $2.475 | 247,000 | |
| $2.52 | +0.02 | +0.8% | $2.50 | $2.61 | $2.46 | 564,200 | |
| $2.50 | +0.12 | +5.0% | $2.39 | $2.535 | $2.39 | 379,000 | |
| $2.38 | +0.07 | +3.0% | $2.30 | $2.405 | $2.27 | 523,200 | |
| $2.31 | -0.10 | -4.1% | $2.41 | $2.44 | $2.30 | 329,900 | |
| $2.41 | -0.06 | -2.4% | $2.48 | $2.48 | $2.371 | 308,000 | |
| $2.47 | -0.02 | -0.8% | $2.48 | $2.50 | $2.40 | 202,000 | |
| $2.49 | -0.01 | -0.4% | $2.50 | $2.51 | $2.43 | 244,100 | |
| $2.50 | 0.00 | 0.0% | $2.53 | $2.54 | $2.46 | 453,435 | |
| $2.50 | +0.11 | +4.6% | $2.41 | $2.54 | $2.345 | 735,926 | |
| $2.39 | +0.04 | +1.7% | $2.38 | $2.415 | $2.37 | 309,300 | |
| $2.35 | -0.10 | -4.1% | $2.45 | $2.47 | $2.33 | 540,000 | |
| $2.45 | +0.05 | +2.1% | $2.44 | $2.515 | $2.43 | 645,000 | |
| $2.40 | +0.01 | +0.4% | $2.36 | $2.41 | $2.31 | 344,000 | |
| $2.39 | -0.02 | -0.8% | $2.41 | $2.42 | $2.32 | 489,500 | |
| $2.41 | 0.00 | 0.0% | $2.39 | $2.435 | $2.37 | 227,900 | |
| $2.41 | +0.01 | +0.4% | $2.43 | $2.46 | $2.33 | 360,700 | |
| $2.40 | -0.05 | -2.0% | $2.38 | $2.47 | $2.38 | 296,900 | |
| $2.45 | -0.01 | -0.4% | $2.48 | $2.515 | $2.41 | 580,700 | |
| $2.46 | -0.01 | -0.4% | $2.44 | $2.525 | $2.42 | 479,000 | |
| $2.47 | +0.06 | +2.5% | $2.38 | $2.475 | $2.38 | 386,700 | |
| $2.41 | +0.01 | +0.4% | $2.39 | $2.49 | $2.385 | 422,900 | |
| $2.40 | -0.04 | -1.6% | $2.46 | $2.50 | $2.33 | 1,108,500 | |
| $2.44 | +0.23 | +10.4% | $2.25 | $2.465 | $2.24 | 1,255,000 | |
| $2.21 | +0.03 | +1.4% | $2.19 | $2.285 | $2.155 | 486,500 |
- Ticker
- gettex:IQT0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Oct 27, 2026
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 32 slides
Calls
Replays
Inhibikase Therapeutics (NASDAQ:IKT) Q2 2024 Earnings Call
Thu, Aug 15, 2024 · 8:00 AM ET
Watch TranscriptInhibikase Therapeutics (NASDAQ:IKT) Q1 2024 Earnings Call
Thu, May 16, 2024 · 8:00 AM ET
Watch TranscriptInhibikase Therapeutics (NASDAQ:IKT) Q4 2023 Earnings Call
Thu, Mar 28, 2024 · 8:00 AM ET
Watch Transcript
Latest news
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
Oct 27, 2026
Closed $1.57 (+3.3%) on Oct 27, 2026
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Oct 20, 2026
Closed $1.66 (-2.9%) on Oct 21, 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026
Closed $2.00 (0.0%) on Oct 5, 2026
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Aug 11, 2026
Closed $2.40 (-2.0%) on Aug 12, 2026
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Jul 23, 2026
Closed $2.33 (+7.4%) on Jul 23, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility
Jul 15, 2026
Closed $2.06 (0.0%) on Jul 15, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Jul 14, 2026
Closed $2.06 (+5.1%) on Jul 14, 2026
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
May 12, 2026
Closed $1.90 (-1.0%) on May 13, 2026
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Apr 7, 2026
Closed $1.76 (-1.7%) on Apr 7, 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
Apr 6, 2026
Closed $1.79 (-0.6%) on Apr 6, 2026
Financings
At-the-market programme of common stock
Aug 11, 2026
Closed: US$50M in the latest tranche
Buyers: RA Capital Management (25,000,000 shares of common stock for gross proceeds of $50 million)
Use of proceeds: With existing cash, to support operations through topline data readout in Part B of the Phase 3 IMPROVE-PAH study
Closed Jul 14, 2026 · Closed Jul 15, 2026 · Closed Aug 11, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 32 slides · September 2026
Investor Presentation (November 2025)
Investor deck · 28 slides · Nov 20, 2025
Investor Presentation (August 2025)
Investor deck · 24 slides · Aug 14, 2025
Investor Presentation (October 2024)
Investor deck · 33 slides · Oct 9, 2024
Inhibikase Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 28 in all · newest Oct 27, 2026 · oldest 2024
- Calls
- 11 calls with a replay · 11 with a transcript · latest Aug 15, 2024
- Decks
- 14 decks · latest September 2026
Where Inhibikase Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IKT · Home listing | NASDAQ | United States | USD |
| gettex:IQT0 · This page | gettex | Germany | EUR |
| BOATS:IKT | BOATS | United States | USD |
| Munich:IQT0 | Munich | Germany | EUR |
| Stuttgart:IQT0 | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Inhibikase Therapeutics, Inc.